Malignant astrocytic glioma: genetics, biology, and paths to treatment.

By F. Furnari, Tim R. Fenton, R. Bachoo, A. Mukasa, Jayne M. Stommel, A. Stegh, William C. Hahn, K. Ligon, D. Louis, C. Brennan and 3 more. Genes & Development, 2007

2,428 citations recorded by the source corpus.

Malignant astrocytic gliomas such as glioblastoma are the most common and lethal intracranial tumors. These cancers exhibit a relentless malignant progression characterized by widespread invasion throughout the brain, resistance to traditional and newer targeted therapeutic approaches, destruction of normal brain tissue, and certain death. The recent confluence of advances in stem cell biology, cell signaling, genome and computational science and genetic model systems have revolutionized our understanding of the mechanisms underlying the genetics, biology and clinical behavior of glioblastoma. This progress is fueling new opportunities for understanding the fundamental basis for development of this devastating disease and also novel therapies that, for the first time, portend meaningful clinical responses.

Subfields: Genetics, Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/a75b4efbf7503f370fe751002ad3a34a00ed7ec3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

In Molecular Biology

In Pulmonary and Respiratory Medicine

Citations in the corpus

Lipid metabolism reprogramming and its potential targets in cancer (2018, background): “This mutant lacks a portion of the extracellular ligand-binding domain [34, 106, 108, 111, 114, 115].”
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. (2010, background): “A subset of 5% of GBM tumors, termed secondary GBM, progress from lower-grade tumors (grade II/III), are seen in younger patients, are more evenly distributed among the sexes, and exhibit longer survival times (reviewed in Adamson et al., 2009; Furnari et al., 2007).”
The Hypoxic Microenvironment Maintains Glioblastoma Stem Cells and Promotes Reprogramming towards a Cancer Stem Cell Phenotype (2009, background): “Glioblastoma is among the most lethal cancers and current treatment modalities are limited in increasing the lifespan of patients.(1,2) We and others have shown that cancer stem cells potentially contribute to glioblastoma treatment failure as cancer stem cells are resistant to radiotherapy and chem”
P53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation (2008, positive): “%) in human high-grade glioma 3 , 16/16 mouse high-grade glimoas showed no Pten expression in tumor cells but robust signal in surrounding non-malignant cells and intratumoral vessels (Fig.”
Comprehensive genomic characterization defines human glioblastoma genes and core pathways (2009, background): “Primary glioblastoma, which comprises more than 90% of biopsied or resected cases, arises de nova without antecedent history of low-grade disease, whereas secondary glioblastoma progresses from previously diagnosed low-grade gliomas 1 • Patients with newly diagnosed glioblastoma have a median surviv”
PTEN and the PI3-kinase pathway in cancer. (2009, background): “Somatic mutation in the second allele of PTEN, which results in biallelic inactivation, occurs in 25% to 40% of glioblastomas (33,48).”
Comprehensive genomic characterization defines human glioblastoma genes and core pathways (2008, background): “Two decades of molecular studies have identified important genetic events in human glioblastomas, including the following: (1) dysregulation of growth factor signalling via amplification and mutational activation of receptor tyrosine kinase (RTK) genes; (2) activation of the phosphatidylinositol-3-O”
Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. (2009, background): “Though there has been success in identifying the disrupted signaling pathways and underlying genetic defects associated with glial tumors (Furnari et al., 2007; Cancer Genome Atlas Research Network, 2008), it remains unclear how these operate in different cellular contexts.”
Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells (2013, background): “The current standard of care for patients with GBM provides only palliation with a median survival of about 15 months (Furnari et al., 2007; Stupp et al., 2005).”
Automated Network Analysis Identifies Core Pathways in Glioblastoma (2010, background): “Alterations within the p53 pathway include mutations and deletions of TP53, homozygous deletion of CDKN2A, and amplifications of MDM2 and MDM4 [2,4].”
Astrocytes: biology and pathology (2009, background): “In a manner consistent with the cancer stem cell hypothesis, there is considerable evidence that only minor populations of cells in primary gliomas are capable of forming a tumor, [76, 223].”